Notice of Hearing Schedule; Passenger Vessel Financial Responsibility, 9415-9416 [2010-4202]

Download as PDF 9415 Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 26, 2010. A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 1. Platte Valley Bancorp, Inc., to become a bank holding company by acquiring 100 percent of the voting shares of Platte Valley Bank, both of North Bend, Nebraska. B. Federal Reserve Bank of San Francisco (Kenneth Binning, Vice President, Applications and Enforcement) 101 Market Street, San Francisco, California 94105–1579: 1. Franklin Resources, Inc., San Mateo, California; to retain 9.53 percent of the voting shares of West Coast Bancorp, and thereby indirectly retain voting shares of West Coast Bank, both of Lake Oswego, Oregon. Board of Governors of the Federal Reserve System, February 25, 2010. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2010–4227 Filed 3–1–10; 8:45 am] BILLING CODE 6210–01–S FEDERAL RESERVE SYSTEM Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/. Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 17, 2010. A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414: 1. Northwest Financial Corp., Arnolds Park, Iowa; to engage de novo through its subsidiary, Northwest Wealth Management, LLC, Arnolds Park, Iowa, in investment advisory and transactional activities, pursuant to sections 225.28(b)(6)(i); (b)(6)(ii); b)(6)(v); (b)(7)(i); (b)(7)(ii) and (b)(9)(ii), all of Regulation Y. Board of Governors of the Federal Reserve System, February 25, 2010. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2010–4226 Filed 3–1–10; 8:45 am] BILLING CODE 6210–01–S FEDERAL MARITIME COMMISSION Notice of Hearing Schedule; Passenger Vessel Financial Responsibility The Commission has established the following allotment of time and order of presentation for the hearing concerning the Commission’s Passenger Vessel Financial Responsibility Program. The hearing will convene at 10 a.m., March 3, 2010, in the Commission’s Main Hearing Room, Room 100, 800 North Capitol Street, NW., Washington, DC 20573. In the event that additional time is needed to hear all participants and allow presenters to field questions from the Commission, an afternoon session will be convened. The due date for submitting the original and 15 copies of participant’s prepared hearing statement is Friday, February 26, 2010. All written submissions, except for confidential business information, will be available for public inspection. Time allotment (in minutes) Company Participant(s) American Cruise Lines Inc. ......................................................... Carnival Corporation & PLC ....................................................... Charles A. Robertson, Chairman & Chief Executive Officer ..... David Bernstein, Senior Vice President & Chief Financial Officer. Ann G. Miller, Law Offices of Ann G. Miller .............................. Terry L. Dale, President and CEO, J. Michael Cavanaugh, Holland & Knight LLP. Ed Welch, Legislative Director ................................................... Crystal Cruises, Inc. .................................................................... Cruise Lines International Association ....................................... WReier-Aviles on DSKGBLS3C1PROD with NOTICES Passenger Vessel Association ................................................... VerDate Nov<24>2008 15:07 Mar 01, 2010 Jkt 220001 PO 00000 Frm 00036 Fmt 4703 Sfmt 9990 E:\FR\FM\02MRN1.SGM 02MRN1 15 15 15 15 15 9416 Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices Karen V. Gregory, Secretary. Committee Information Hotline (the hotline). The hotline provides the public with access to the most current information available on FDA advisory committee meetings. This notice supersedes all previously published announcements of FDA’s Advisory Committee Information Hotline. [FR Doc. 2010–4202 Filed 3–1–10; 8:45 am] BILLING CODE 6730–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES FOR FURTHER INFORMATION CONTACT: Michael F. Ortwerth, Director, Advisory Committee Oversight and Management Staff (HF–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1220. Food and Drug Administration [Docket No. FDA–2010–N–0001] Advisory Committee Information Hotline AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing that we have revised the Advisory The Advisory Committee Information Hotline can be accessed by dialing 1– 800–741–8138 or 301–443–0572. The advisory committee meeting information and information updates can also be accessed via FDA’s Advisory SUPPLEMENTARY INFORMATION: Committee Internet site at https:// www.fda.gov/AdvisoryCommittees/ default.htm. Each advisory committee is assigned a 10-digit number. This 10-digit number will appear in each individual notice of meeting. The public can obtain information about a particular advisory committee meeting by using the committee’s 10-digit number. Information on the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made. The following is a list of each advisory committee’s 10-digit number to be used when accessing the hotline. The list has been updated to add the newly established advisory committee in the Center for Tobacco called the Tobacco Products Scientific Advisory Committee. Advisory Committee 10-Digit Access Number OFFICE OF THE COMMISSIONER Pediatric Advisory Committee 8732310001 Risk Communication Advisory Committee 8732112560 Science Board to the FDA 3014512603 CENTER FOR BIOLOGICS EVALUATION AND RESEARCH Allergenic Products Advisory Committee 3014512388 Blood Products Advisory Committee 3014519516 Cellular, Tissue & Gene Therapies Advisory Committee 3014512389 Transmissible Spongiform Encephalopathies Advisory Committee 3014512392 Vaccines and Related Biological Products Advisory Committee 3014512391 CENTER FOR DRUG EVALUATION AND RESEARCH 3014512530 Antiviral Drugs Advisory Committee 3014512531 Arthritis Advisory Committee 3014512532 Cardiovascular and Renal Drugs Advisory Committee 3014512533 Dermatologic and Ophthalmic Drugs Advisory Committee 3014512534 Drug Safety and Risk Management Advisory Committee 3014512535 Endocrinologic and Metabolic Drugs Advisory Committee 3014512536 Gastrointestinal Drugs Advisory Committee 3014512538 Nonprescription Drugs Advisory Committee 3014512541 Oncologic Drugs Advisory Committee 3014512542 Peripheral and Central Nervous System Drugs Advisory Committee 3014512543 Pharmaceutical Science & Clinical Pharmacology, Advisory Committee for (formerly Advisory Committee for Pharmaceutical Science) VerDate Nov<24>2008 3014512529 Anti-Infective Drugs Advisory Committee WReier-Aviles on DSKGBLS3C1PROD with NOTICES Anesthetic and Life Support Drugs Advisory Committee 3014512539 15:07 Mar 01, 2010 Jkt 220001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\02MRN1.SGM 02MRN1

Agencies

[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Pages 9415-9416]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-4202]


=======================================================================
-----------------------------------------------------------------------

FEDERAL MARITIME COMMISSION


Notice of Hearing Schedule; Passenger Vessel Financial 
Responsibility

    The Commission has established the following allotment of time and 
order of presentation for the hearing concerning the Commission's 
Passenger Vessel Financial Responsibility Program. The hearing will 
convene at 10 a.m., March 3, 2010, in the Commission's Main Hearing 
Room, Room 100, 800 North Capitol Street, NW., Washington, DC 20573. In 
the event that additional time is needed to hear all participants and 
allow presenters to field questions from the Commission, an afternoon 
session will be convened.
    The due date for submitting the original and 15 copies of 
participant's prepared hearing statement is Friday, February 26, 2010. 
All written submissions, except for confidential business information, 
will be available for public inspection.

------------------------------------------------------------------------
                                                          Time allotment
            Company                   Participant(s)        (in minutes)
------------------------------------------------------------------------
American Cruise Lines Inc......  Charles A. Robertson,                15
                                  Chairman & Chief
                                  Executive Officer.
Carnival Corporation & PLC.....  David Bernstein, Senior              15
                                  Vice President & Chief
                                  Financial Officer.
Crystal Cruises, Inc...........  Ann G. Miller, Law                   15
                                  Offices of Ann G.
                                  Miller.
Cruise Lines International       Terry L. Dale,                       15
 Association.                     President and CEO, J.
                                  Michael Cavanaugh,
                                  Holland & Knight LLP.
Passenger Vessel Association...  Ed Welch, Legislative                15
                                  Director.
------------------------------------------------------------------------



[[Page 9416]]

Karen V. Gregory,
Secretary.
[FR Doc. 2010-4202 Filed 3-1-10; 8:45 am]
BILLING CODE 6730-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.